文献速递生殖医学

匹配倾向性评分设计比较非整倍体植入前遗传学检测后的妊娠结局

Comparison of pregnancy outcomes following preimplantation genetic testing for aneuploidy using a matched propensity score design.
PubMed 文献 · Hum Reprod · 2020-01-01

该回顾性队列研究纳入8227名接受自体IVF且有受精胚胎的女性,用倾向性评分1:1匹配比较使用与未使用PGT-A者的妊娠结局。总体上PGT-A组胚胎移植可能性较低(RR 0.78),但临床妊娠(RR 1.15)和活产(RR 1.21)可能性较高。≥38岁女性使用PGT-A活产可能性为未使用者的1.67倍,35-37岁为1.27倍,<35岁两组无显著差异(RR 0.91)。

要点

  • ≥38岁女性使用PGT-A活产可能性为未使用者的1.67倍(RR 1.67,95%CI 1.31-2.13)。
  • 35-37岁女性使用PGT-A活产可能性较高(RR 1.27,95%CI 1.05-1.54)。
  • <35岁女性使用与未使用PGT-A活产可能性无显著差异(RR 0.91,95%CI 0.78-1.06)。

核心结论

  • 在35岁及以上接受自体IVF且有受精胚胎的女性中,PGT-A与更高的活产概率相关;<35岁女性中未见此关联。

研究设计与样本

  • 回顾性队列研究,纳入2011年1月1日至2017年10月31日期间在本机构首次取卵并拥有受精胚胎的自体IVF女性,分析仅限与首次取卵相关的周期。
  • 分析队列共8227名女性,采用多变量逻辑回归计算PGT-A倾向性评分,按1:1比例匹配使用与未使用PGT-A的女性。
  • 采用对数二项回归比较两组胚胎移植、临床妊娠、流产和活产的累积发生率,并按<35岁、35-37岁、≥38岁分层重复分析。

主要发现

  • 总体上,使用PGT-A的女性胚胎移植可能性显著较低(RR 0.78,95%CI 0.73-0.82),但临床妊娠(RR 1.15,95%CI 1.04-1.28)和活产(RR 1.21,95%CI 1.08-1.35)可能性较高。
  • ≥38岁女性中,使用PGT-A者活产可能性为未使用者的1.67倍(RR 1.67,95%CI 1.31-2.13)。
  • 35-37岁女性中,使用PGT-A者活产可能性较高(RR 1.27,95%CI 1.05-1.54)。
  • <35岁女性中,使用与未使用PGT-A者活产可能性无显著差异(RR 0.91,95%CI 0.78-1.06)。

临床怎么用

  • 作者认为35岁及以上女性可能从PGT-A中获益。
  • 作者指出更大规模的研究可能识别出其他可能从PGT-A中获益的女性亚组。

局限性

  • 无法从患者记录中提取若干潜在混杂变量(如抗苗勒管激素水平和既往IVF治疗),可能导致残余混杂。
  • 分析仅限于与首次取卵相关的周期,无法估计多次取卵周期的活产累积发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does preimplantation genetic testing for aneuploidy (PGT-A) increase the likelihood of live birth among women undergoing autologous IVF who have fertilized embryos? SUMMARY ANSWER: PGT-A is associated with a greater probability of live birth among women 35 years old and older who are undergoing IVF. WHAT IS KNOWN ALREADY: Previous studies evaluating the association between PGT-A and the incidence of live birth may be prone to confounding by indication, as women whose embryos undergo PGT-A may have a lower probability of live birth due to other factors associated with their increased risk of aneuploidy (e.g. advancing age, history of miscarriage). Propensity score matching can reduce bias where strong confounding by indication is expected. STUDY DESIGN, SIZE, DURATION: We conducted a retrospective cohort study utilizing data from women who underwent autologous IVF treatment, had their first oocyte retrieval at our institution from 1 January 2011 through 31 October 2017 and had fertilized embryos from this retrieval. If a woman elected to use PGT-A, all good quality embryos (defined as an embryo between Stages 3 and 6 with Grade A or B inner or outer cell mass) were tested. We only evaluated cycles associated with the first oocyte retrieval in this analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Our analytic cohort included 8227 women. We used multivariable logistic regression to calculate a propensity score for PGT-A based on relevant demographic and clinical factors available to the IVF provider at the time of PGT-A or embryo transfer. We used the propensity score to match women who did and did not utilize PGT-A in a 1:1 ratio. We then used log-binomial regression to compare the cumulative incidence of embryo transfer, clinical pregnancy, miscarriage and live birth between women who did and did not utilize PGT-A. Because the risk of aneuploidy increases with age, we repeated these analyses among women <35, 35-37 and ≥38 years old based on the Society for Assisted Reproductive Technology's standards. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, women with fertilized embryos who used PGT-A were significantly less likely to have an embryo transfer (risk ratios (RR): 0.78; 95% CI: 0.73, 0.82) but were more likely to have a cycle that resulted in a clinical pregnancy (RR: 1.15; 95% CI: 1.04, 1.28) and live birth (RR: 1.21; 95% CI: 1.08, 1.35) than women who did not use PGT-A. Among women aged ≥38 years, those who used PGT-A were 67% (RR: 1.67; 95% CI: 1.31, 2.13) more likely to have a live birth than women who did not use PGT-A. Among women aged 35-37 years, those who used PGT-A were also more likely to have a live birth (RR: 1.27; 95% CI: 1.05, 1.54) than women who did not use PGT-A. In contrast, women <35 years old who used PGT-A were as likely to have a live birth (RR: 0.91; 95% CI: 0.78, 1.06) as women <35 years old who did not use PGT-A. LIMITATIONS, REASONS FOR CAUTION: We were unable to abstract several potential confounding variables from patients' records (e.g. anti-Mullerian hormone levels and prior IVF treatment), which may have resulted in residual confounding. Additionally, by restricting our analyses to cycles associated with the first oocyte retrieval, we were unable to estimate the cumulative incidence of live birth over multiple oocyte retrieval cycles. WIDER IMPLICATIONS OF THE FINDINGS: Women aged 35 years or older are likely to benefit from PGT-A. Larger studies might identify additional subgroups of women who might benefit from PGT-A. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for this study. D.S. reports that he is a member of the Cooper Surgical Advisory Board. The other authors report no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Haviland MJ, Murphy LA, Modest AM, et al. Comparison of pregnancy outcomes following preimplantation genetic testing for aneuploidy using a matched propensity score design. Hum Reprod. 2020. PMID: 32856053. doi:10.1093/humrep/deaa161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。